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Abstract
Major depressive disorder is a debilitating disease. Unfortunately, treatment with antidepressants (ADs) has limited
therapeutic efficacy since resistance to AD is common. Research in this field is hampered by the lack of a reliable natural
animal model of AD resistance. Depression resistance is related to various factors, including the attendance of
cardiovascular risk factors and past depressive episodes. We aimed to design a rodent model of depression resistance to
ADs, associating cardiovascular risk factors with repeated unpredicted chronic mild stress (UCMS). Male BALB/c mice were
given either a regular (4% fat) or a high fat diet (45% fat) and subjected to two 7-week periods of UCMS separated by 6
weeks. From the second week of each UCMS procedure, vehicle or fluoxetine (10 mg/kg, i.p.) was administrated daily. The
effects of the UCMS and fluoxetine in both diet conditions were assessed using physical (coat state and body weight) and
behavioural tests (the reward maze test and the splash test). The results demonstrate that during the second procedure,
UCMS induced behavioural changes, including coat state degradation, disturbances in self-care behaviour (splash test) and
anhedonia (reward maze test) and these were reversed by fluoxetine in the regular diet condition. In contrast, the high-fat
diet regimen prevented the AD fluoxetine from abolishing the UCMS-induced changes. In conclusion, by associating
UCMS—an already validated animal model of depression—with high-fat diet regimen, we designed a naturalistic animal
model of AD resistance related to a sub-nosographic clinical entity of depression.
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Introduction
Major depressive disorder is a debilitating disease with a
prevalence estimated to be as high as 16.2% according to the
National Comorbidity Survey [1]. Unfortunately, the therapeutic
efficacy of antidepressants (ADs) is unsatisfactory, since most
patients fail to achieve a full remission when treated, mostly being
non- or partial responders. Remission (i.e., full resolution of
symptoms) occurs in only one third of the patients after treatment
with a single drug [2,3]. AD resistance is related to various factors,
including specific diagnostic entities. AD resistance is more
frequent in some sub-nosographic disorders such as vascular
depression. In this subtype of depression, it is suggested that the
presence of brain cortical lesion of vascular origin predisposes,
precipitates, or perpetuates a depressive state and has a negative
impact on treatment outcome [4,5,6].
Furthermore, treatment-resistant major depression is also
frequently described in patients with acute coronary heart disease,
and seems to increase risk of mortality after acute coronary
syndrome [7]. Moreover, cardiovascular risk factors like aging,
smoking, hypertension, diabetes, hypercholesterolemia and ad-
vanced heart disease predict a poor response to fluoxetine/
citalopram treatment and lack of remission [8,9]. Although low
cholesterol levels have been reported in depressed subjects [10,11],
in several studies, hypercholesterolemia, a risk factor for
cardiovascular disease, was associated with a poor outcome
following AD in major depression [12,13]. Finally, it seems that
an increased number of past depressive episodes can also be
associated with resistance to AD [14,15]. According to these
results it seems that both the occurrence of vascular risk factors
and the number of repeated depressive episodes can increase the
risk of resistance to AD in major depression. However, research in
this field is hampered by the lack of animal models of AD-
resistance.
Several animal models of treatment-resistant depression have
been proposed. Some are based on the invalidation of genes
encoding for proteins involved either in the brain ADs penetration
[16] or in the ADs molecular target [17,18,19,20]. In some
instances, mutant mice only show a blunted response to AD and
not a total suppression of the AD effect [21,22,23,24]. The main
limit of this approach, based on the invalidation of single gene, is
that it only partially mimics the human condition. Other
approaches looked at the alteration of particular behavioural
markers (for example high responders to novelty decreased
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disrupted neurogenesis do not respond to monoaminergic AD:
[17,26]. However, all of these models are mostly concerned with
providing a mechanism explaining the AD resistance and not in
proposing a naturalistic animal model of AD resistance related to
sub-nosographic clinical entities.
For studying depressive disorders, the unpredictable chronic
mild stress (UCMS) animal model has been shown to be valid,
reliable and sensitive [27]. UCMS involves subjecting mice to a
period of mild socio-environmental stressors. This procedure
replicates several depression-related behavioural and physiological
impairments which are reversed by chronic (but not acute) AD
treatment [28,29,30,31]. Furthermore, since cardiovascular risk
factors are related to AD resistance, the association of the UCMS
procedure with a cardiovascular risk factor known to induce
hypercholesterolemia in mice such as a high fat diet regimen
provides a powerful tool to describe a model of ‘‘treatment-
resistant depression’’. The development of a naturalistic animal
model of AD resistance related to sub-nosographic clinical entities
will contribute to the development of new drugs which may be
useful in the treatment of vascular depression.
The main objective of the present study was to evaluate the
ability of chronic AD treatment with fluoxetine to reverse UCMS-
induced depression-like behaviour in BALB/c mice when
associating both repeated episodes of UCMS and a high fat diet
regimen. As a 6-month period of a high fat diet regimen is
necessary to induce cardiovascular alterations in BALB/c mice
[32], we planned to repeat the UCMS procedure twice in this time
period, with a UCMS-free period between the two. We evaluated
the response to both UCMS and high fat diet via several validated
measures, including physical measures (coat state degradation and
body weight) and behavioural tests such as the splash test (decease
in total grooming time) and the reward maze test (decreased
latency to chew a chocolate cookie).
Methods
Animals
The subjects were 71 experimentally naive male BALB/c mice
(7–9 weeks old) (Centre d’e ´levage Janvier, Le Genest Saint Isle,
France) housed in groups of 4 and maintained under standard
laboratory conditions (12 hrs. light-dark cycle, light on at 20:00;
Temperature =22 +/22uC) for 1 week prior to the beginning of
the experiment. Food and water were freely available. All
behavioural testing occurred during the dark phase of the light–
dark cycle. All of the experiments are in agreement with the
veterinary service (agreement number: B37-261-2) and were
carried out in strict compliance with the European Community
Council directive 86/609/EEC and with French legislation from
the Ministe `re de l’Agriculture.
Drug
The selective serotonin reuptake inhibitor Fluoxetine hydro-
chloride (Sequoia) was freshly prepared every day in saline (NaCl
0.9%) and administrated intraperitoneally (IP, 10 mg/kg) in a
volume of 10 ml/kg. Vehicle animals received an IP injection of
0.9% saline in a volume of 10 ml/kg.
General procedure (Figure 1)
The mice were randomized into regular diet (RD, 4% fat,
DIETEX France) and high fat diet (HFD, 45% fat and 0.15%
cholesterol, DIETEX France) conditions. In each condition, the
mice were divided in four groups: Control/NaCl (RD: n=9 and
HFD: n=10), Control/Fluoxetine (RD: n=10, HFD: n=8),
UCMS/NaCl (RD: n=8, HFD: n=10), and UCMS/Fluoxetine
(RD: n=6, HFD: n=10). The control group was maintained in
standard laboratory conditions while the mice in the UCMS group
were placed in small, individual cages (8613.568.1 cm). We
performed two 7-week UCMS procedures separated by a 6 week
Figure 1. General procedure and experimental groups. In each regular diet and high fat diet condition, half of the mice were submitted to two
7-week periods of unpredictable chronic mild stress (UCMS) procedures separated by 6 weeks. Control mice were kept in standard laboratory
conditions. After two weeks of UCMS, mice received either fluoxetine treatment (10 mg/kg, i.p.) or vehicle treatment (NaCl, 0.9%, i.p.). Treatments
were administered daily during the last 5 weeks of the UCMS protocol and the same treatment procedure was performed during the second UCMS
phase. Coat state and body weight were evaluated weekly and behaviour was assessed using the reward maze test and the splash test. One session
of the reward maze test was performed at the end of the first UCMS procedure (Session R1) and one session at the end of the second UCMS
procedure (Session R2). The splash test was performed at the beginning (session S1 for the first UCMS procedure and session S3 for the second UCMS
procedure) and the end (session S2 for the first UCMS procedure and session S4 for the second UCMS procedure) of each UCMS procedure.
doi:10.1371/journal.pone.0010404.g001
Fluoxetine Resistance in Mice
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weeks of the UCMS regimen were drug-free. Treatment was
initiated on the third week of UCMS and continued up to the end
of the 7 weeks. The same procedure was repeated during the
second UCMS regimen. Coat state and body weight was assessed
weekly until the end of the second UCMS regimen. During the
two UCMS procedures, behavioural tests were carried out as
follows: the splash test and the reward maze test.
Unpredictable chronic mild stress
The mice were subjected to various and repeated unpredictable
stressors several times a day during the two 7-week UCMS
procedures. The stressors were: altered bedding (change or
removal of sawdust, damp sawdust, substitution of sawdust with
21uC water), cage tilting (45u), cage exchange (mice were placed in
the empty cage of another male), altered length and time of light/
dark cycle [26,31,33].
Coat state and body weight
The coat state and the body weight of each animal were
evaluated weekly until the end of the second UCMS procedure.
The coat-state evaluation involved the assessment of eight different
body parts: head, neck, dorsal coat, ventral coat, tail, forepaws,
hind paws and genital region. For each body area, a score of 0 was
attributed for a coat in good condition or a score of 1 for a dirty
coat. The total score was defined as the sum of the scores for each
body part. This index has been pharmacologically validated in
previous studies using BALB/c mice [26,33,34].
Splash Test
The splash test, performed under a red light (230 V, 15 W),
consists of squirting a 10% sucrose solution on the dorsal coat of a
mouse in its home cage. Because of its viscosity, the sucrose
solution dirties the mouse fur and animals initiate grooming
behaviour. After applying sucrose solution, the time spent
grooming was recorded for a period of 5 minutes as an index of
self-care and motivational behaviour. The splash test was carried
out at the beginning (S1 for UCMS 1 and S3 for UCMS 2) and at
the end (S2 for UCMS1 and S4 for UCMS 2) of each UCMS
procedure. The splash test, pharmacologically validated, demon-
strates that UCMS decreases grooming behaviour [17,26,31,35], a
form of motivational behaviour considered to parallel with some
symptoms of depression such as apathetic behaviour [36].
Moreover, UCMS-induced grooming perturbation is associated
with hedonic reactivity in the sucrose preference test and increased
immobility in the force swim test [37,38].
Reward maze test
The reward maze test is used to assess UCMS-induced effects
on the motivation to obtain a reward. This test consists in assessing
the motivation for a palatable stimulus (a chocolate cookie) by
measuring the latency before chewing the cookie. The reward
maze test requires a device containing three aligned chambers
with the same dimensions (19619620 cm). The only difference in
the chambers is the colour of the walls and the floor: white for the
first chamber, grey for the second and black for the third. The
three chambers are linked by two openings via a door which is
controlled by the experimenters. The device is illuminated by a
200-lux white light. To familiarize the mice with the palatable
stimulus, small portion of cookie is placed in the homecage every 2
day for a period of 2.5 weeks starting 4.5 weeks before the first
session. At the time of testing, a small piece of chocolate cookie is
positioned at the centre of the black room. The white room is the
departure compartment and the mouse is placed with its head
facing away from the opening. The test lasts five minutes
maximum; the door separating the departure chamber and the
intermediate chamber was closed after the transition of the mouse
(if a mouse did not enter after 2 minutes, it was gently guided
toward the intermediate room).
The validation of this test was demonstrated by the stronger
drive to chew a chocolate cookie than to chew a regular food pellet
as a robust reduction of the chewing latency with the chocolate
cookie when compared with the regular food. In the UCMS
paradigm, the reward maze test can assess multiple behavioural
dimensions: 1) anxiety-like state (latency to pass the first door), 2)
locomotion and exploratory behaviour (number of passage trough
the second door) and 3) anhedonia (latency to chew the chocolate
cookie in the UCMS mice vs Control mice). This test was validated
in previous study in our laboratory demonstrating that a 7-week
UCMS has no effect on the anxiety-like and exploratory behaviour
but significantly increases the latency to chew the cookie. These
results indicate that UCMS induces anhedonia [31].
In our experiment, we performed one session at the end of each
UCMS procedure (R1 at the end of the first UCMS procedure
and R2 at the end of the second UCMS procedure). During the
two sessions, we recorded: 1) the latency to pass the first door as an
index of anxiety behaviour, 2) the number of passage through the
second door as an index of locomotion and exploratory behaviour
and 3) the latency to chew the cookie as an index of anhedonia.
Statistical analysis
The results are expressed as the mean +/2 SEM (standard
error of the mean). Since the sample-size was small (6,n,10) and
did not follow a normal distribution, we used a non-parametric
analysis. Behaviour among all groups was compared using the
Kruskall-Wallis test and compared among the different sessions in
each group using the Friedman test (multiple samples). The
Kruskall-Wallis was followed by the U of Mann-Witney test and
the Friedman test was followed by the Wilcoxon test for two per
two comparisons when required. Differences were considered as
statistically significant at p,.05.
Results
Coat state and body weight
The statistical analysis of changes in coat state (Figure 2)
between the regular diet and the high fat diet groups were
performed separately because of the texture difference between the
two diets. The high fat diet was friable and thus readily dirtied the
fur of the mice. This explains why, in the high fat diet groups, the
coat state score was generally higher than in the regular diet
groups.
In the regular diet group, the Kruskall-Wallis test indicates a
significant difference between groups at the end of the first and the
second UCMS procedure (week 7: H3, 33=25.1, p,0.001; week
20: H3, 33=20.2, p,0.001). The UCMS regimen induced a
deterioration of the coat state (week 7: U=0.0, p,.001; week 20:
U=1.5, p,.001). Importantly, fluoxetine treatment significantly
reversed the deterioration of the coat state induced by UCMS
(week 7: U=8, p,.05; week 20: U=6.5, p,.01).
Similarly, in the high fat diet group, the Kruskall-Wallis test
indicates a significant difference between groups at the end of both
the first and the second UCMS regimen (week 7: H3, 38=8.5,
p,.05; week 20: H3, 38=15.9, p,0.01). However, the UCMS-
induced coat state degradation (week 7: U=16, p,.01; week 20:
U=10.5, p,.01) was not significantly reversed by chronic
fluoxetine (week 7: U=32, ns; week 20: U=46.5; ns).
Fluoxetine Resistance in Mice
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group (Friedman test: Control/NaCl: RD: X
2
9, 20=114.9,
p,.001; HFD: X
2
10, 20=38.8, p,.01; Control/fluoxetine: RD:
X
2
9, 20=159.6, p,.001; HFD: X
2
7, 20=59.7, p,.001; UCMS/
NaCl: RD: X
2
8, 20=127.1, p,.001; HFD: X
2
10, 20=70.1,
p,.001; UCMS/fluoxetine: RD: X
2
10, 20=89.2, p,.01; HFD:
X
2
10, 20=117.3,p,.001). The Kruskall-Wallis test failed to establish
any difference between groups at the end of the first UCMS procedure
(week 7: H7, 71=11.8, ns), and at the end of the second UCMS
procedure (week 20: H 7, 71=12.6, ns) (data not shown).
Splash test
The Friedman test indicates a significant difference over the
four sessions of the splash test for each group (Control/NaCl: RD:
X
2
9, 3=16.9, p,.001; HFD: X
2
10, 3=20.5, p,.001; Control/
fluoxetine: RD: X
2
10, 3=17.5, p,.001; HFD: X
2
8, 3=15.9,
p,.01; UCMS/NaCl: RD: X
2
8, 3=7.5, p=.05; HFD: X
2
10, 3=
9.5, p,.05; UCMS/fluoxetine: RD: X
2
6, 3=12.6, p,.01; HFD:
X
2
10, 3=16.7, p,.001).
During the first UCMS procedure, the total grooming time
increased between the beginning(Session S1)and the end (Session S2)
of the regimen in each group suggesting an increase in the motivation
for grooming and the fact that the mice became used to the sucrose
solution (Figure 3A, Control/NaCl: RD: T=2, p,.01; HFD: T=2,
p,.01; Control/fluoxetine: RD: T=7, p,.05; HFD: T=1, p,.01;
UCMS/NaCl: RD: T=0.0, p,.05; HFD: T=0.0, p,.01; UCMS/
fluoxetine: RD: T=0.0, p,.05; HFD: T=0.0, p,.01).
During the second UCMS procedure, we also found an increase
in the total time of grooming behaviour in control mice who
received a regular or a high fat diet (Figure 3B, Control/NaCl:
RD: T=5, p,.05; HFD: T=0.0, p,.01; Control/fluoxetine: RD:
T=0.0, p,.01; HFD: T=1, p,.01) while UCMS abolished this
increase in grooming motivation (RD: T=5, ns; HFD: T=12, ns).
Fluoxetine restored the total grooming time to the unstressed level
in UCMS mice who received a regular diet, but this was not
observed in the mice with the high fat diet (RD: T=0.0, p,.05;
HFD: T=24, ns) suggesting that a high fat diet prevents the
reversal effect of fluoxetine on repeated UCMS-induced grooming
disturbance.
Reward maze test
Regarding the latency to pass the first door and the number of
passage through the second door, the Kruskall-Wallis tests failed to
establish any differences between groups both at the end of the first
and at the end of the second UCMS procedure (Latency to pass
the first door: S1: H7, 71=8.4, ns; S2: H7, 71=5.6, ns. Number of
passage: S1: H7, 71=8.7, ns; S2: H7, 71=13.3, ns). These results
demonstrate that both high fat diet, UCMS and fluoxetine does
not induce an anxiety-like state and perturbation of the locomotor
and exploratory behaviour (Data not shown).
Regarding the latency for chewing the chocolate cookie at the
end of the first UCMS regimen, the Kruskall-Wallis test indicates
no significant difference between the groups (S1: H7, 71=9.3, ns).
However, during the second UCMS procedure, the latency in
Figure 2. Coat state changes. The coat state scores (Mean +/2 SEM) at the end of the two unpredictable chronic mild stress (UCMS) procedures
are presented for both the regular diet (left) and the high fat diet (right) conditions for Control and UCMS groups treated or not with fluoxetine
(10 mg/kg, administrated daily during the last 5 weeks of each UCMS procedure). *p,.05: comparison between the control and UCMS groups, from
the same diet and treatment conditions. #p,.05: comparison between NaCl and fluoxetine-treated groups, from the same UCMS condition.
doi:10.1371/journal.pone.0010404.g002
Fluoxetine Resistance in Mice
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groups at the end of the regimen (Figure 4, S2: H7, 71=19.4,
p,.01). In the control groups, nor high fat diet and fluoxetine
treatment induced a modification of the latency to chew the cookie
(HFD vs RD: Control, NaCl: U=26, ns Control, fluoxetine:
U=29, ns. NaCl vs fluoxetine: Control, RD: U=41, ns; Control
HFD: U=31.5, ns) indicating that no anhedonic effect was
induced by the high fat diet. The UCMS significantly increased
the latency to chew the reward in both the regular and the high fat
diet conditions (RD: U=12, p,.05; HFD: U=19, p,.05).
Fluoxetine only counteracted this effect in mice who received a
regular diet (RD: U=5, p,.05; HFD: U=45, ns). These results
indicate that high fat diet prevents the reversal effect of fluoxetine
on UCMS-induced anhedonia.
Discussion
Based on the hypothesis that cardiovascular risk factors induce
poor response to AD treatment in depressed subjects, the main
objective of the present study was to develop a naturalistic animal
model of AD resistance associating UCMS, a valid animal model of
depression,withcardiovascularriskfactors,especiallythrougha high
fat diet regimen. A high fat diet regimen inducing hypercholester-
olemia is considered as a risk factor for the development of
atherosclerosis. However in mice, the susceptibility to high fat diet is
strain dependant. The BALB/c mice that are the most sensitive to
the UCMSprocedure needa longerperiod ofhigh fat diettoreact of
the cardiovasculareffectsofthisdiet [32].To ensure the effectiveness
of the high fat diet and since resistance to AD is increased with
recurrent depressive episodes, we designed a two UCMS procedure
in BALB/c mice to mimic recurrent depression in humans. Our
results clearly demonstrate that UCMS-induced behavioural
changes including coat state degradation, disturbances in grooming
motivation (splash test) and decrease in the motivation to obtain a
palatable stimulus (reward maze test), were all reversed by fluoxetine
treatment in mice subjected to a regular diet. However, in all these
behavioural tests, a high fat diet regimen abolished the ability of the
AD fluoxetine to reverse UCMS-induced depressive-like state at the
end of the second period of the UCMS procedure.
Does fluoxetine reverse UCMS-induced depression-like
behaviour?
In the regular diet condition, in spite of difference in the time of
occurrence, the behavioural alterations induced by UCMS
observed in this study replicate the behavioural changes reported
in previous studies using the UCMS protocol in mice
[26,31,33,34,35]. Ordinarily, a single UCMS regimen is sufficient
to induce behavioural alterations, which was replicated here on the
coat state. However, the UCMS-effects in the splash test and in the
reward maze test were observed only after the second challenge.
The late-onset apparition of the UCMS effect can be explained by
the number, the intensity and the frequency of the different stressors
application: indeed, as mice were exposed to a second UCMS, we
reduced the severity of the stressors, mainly for ethical reasons.
UCMS and fluoxetine produced their usual effect on the coat
state test, since the UCMS-induced coat state degradation was
prevented by fluoxetine during both the first and the second UCMS
procedure. On the body weight, the absence of UCMS and
fluoxetine effect is in accordance to other studies using fluoxetine
treatment in the UCMS model of depression [34,39]. The results
obtained in the splash test suit those of the coat state since UCMS-
induced disturbance in grooming behaviour was reversed by
fluoxetine treatment. Indicating a loss of motivational and self care
behaviour in mice subjected to two UCMS procedure, the
disturbance in grooming behaviour is considered to parallel the
Figure 3. Total grooming time in the splash test as an index of motivational and self-care behaviour. The grooming time (Mean +/2
SEM) is presented for the control and the unpredictable chronic mild stress (UCMS) groups treated or not with fluoxetine (10 mg/kg, administrated
daily during the last 5 weeks of each UCMS procedure) in the regular and high fat diet conditions. A) Before (S1) and after (S2) the first UCMS
procedure. *p,.05: comparison between S1 and S2 for each group. B) Before (S3) and after (S4) the second UCMS procedure. *p,.05: comparison
between S3 and S4 for each group.
doi:10.1371/journal.pone.0010404.g003
Fluoxetine Resistance in Mice
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Therewardmazetesttakesadvantageofmultiplemeasurestogivea
more accurate analysis of the UCMS-induced effect on the
behaviour, and particularly on anhedonia, which represents a core
symptom of human depression. Our results show that UCMS
procedure does not induce an anxiety-likestate and perturbations of
locomotor and exploratory behaviour. However, UCMS induced
anhedonia, an effect that was counteracted by fluoxetine treatment.
Taken together, these results suggest through multiple behavioral
readouts that chronic AD treatment is effective in reversing a
depression-like phenotype induced by UCMS.
In our study, the behavioural alterations induced by two UCMS
procedures results in symptoms paralleling human depression and
the pharmacological reversal with chronic fluoxetine models the
successful treatment of recurrent depression. Furthermore, this
model provides a powerful tool to describe a model of ‘‘treatment-
resistant depression’’ based on the hypothesis that cardiovascular
risk factors-induced AD resistance.
Does the high fat diet regimen induce depression
resistance to fluoxetine treatment?
In the high fat diet conditions, UCMS induced behavioural
alterations similar to those observed in the regular diet condition.
However, the high fat diet regimen prevented chronic fluoxetine
treatment from reversing UCMS-induced depression-like behaviour.
This result cannot be explained by the cumulative period of UCMS
and the previous treatment and withdrawal to fluoxetine since the
fluoxetine resistance was not observed in the regular diet condition.
In the coat state test, fluoxetine was unable to improve UCMS-
induced coat state degradation during the first and the second
UCMS procedure in mice fed a high fat diet. However, the
deterioration of the coat state induced by the crisp food texture
itself makes this variable difficult to interpret as the observed-effect
might be unspecific and unrelated to depressive-like state. In the
splash test, which also represents an index of grooming behaviour,
results clearly indicate that the UCMS-induced grooming
disturbance was not reversed by fluoxetine treatment at the end
of the second procedure. In this test, where the effect of the food
texture was excluded as an explanation to the observed effects,
only the high fat diet regimen can explain the fluoxetine resistance
in reversing motivational and self-care behaviour. Finally, in the
reward maze test, we found that high fat diet per se has no
anhedonic effect in spite of an increase chewing latency in the
control mice. This effect can be explained by the difference in
palatability between the regular and the high fat diet which could
interfere with the behavioural changes observed. Nevertheless, the
UCMS-induced increase of the chewing latency for the cookie in
both conditions can be interpreted as UCMS-induced anhedonic
behaviour. Similar to the regular diet conditions, UCMS-induced
anhedonia in the high fat diet condition, however, in contrast,
fluoxetine was unable to reverse these effects of UCMS in mice
who received a high fat diet regimen.
In the high fat diet conditions, through multiple behavioural
paradigms, we demonstrated that a high fat diet prevented chronic
fluoxetine treatment from reversing UCMS-induced depression-
like phenotype. These results are important because they mimic
AD resistance induced by vascular risk factors. The hypothesis of
AD resistance induced by vascular risk factors is based on a
number of clinical studies which demonstrate the same effect on
patients with vascular risk factors or suffering from cardiovascular
Figure 4. Latency to chew a cookie in the reward maze test as an index of anhedonia. The latency to chew the chocolate cookie (Mean +/2
SEM) is given for the session performed at the end of the second unpredictable chronic mild stress (UCMS) procedure (R2). The results are presented
for the Control and UCMS mice under a regular or a high fat diet regimen who receive during the last 5 weeks of each UCMS procedure daily injection
of either NaCl (9%) or Fluoxetine (10 mg/kg). *p,.05: Comparison to the control/NaCl group in the regular diet condition. #p,.05: Comparison
between UCMS/NaCl and UCMS/fluoxetine groups in the same diet condition.
doi:10.1371/journal.pone.0010404.g004
Fluoxetine Resistance in Mice
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cerebrovascular lesions show increased resistance to both AD
treatment and electroconvulsive therapy [5,6,40,41,42]. AD
resistance is also associated with the presence of vascular risks
factors. A high incidence of depression has been reported when
associated with the total burden of vascular risk factors [43] and
this so-called cardiovascular risk score (sum of vascular risk factors
including aging, smoking cigarette, history family of premature
vascular disease, hypertension, diabetes and hypercholesterolemia)
is associated with low rates of remission [9]. Indeed, poor long-
term outcomes of depressive symptoms and low rates of remission
with selective serotonin reuptake inhibitor (SSRI) treatment are
associated with cumulated cardiovascular risk factors and can be
predicted by the burden of cardiac disease [8,44].
By mimicking clinical data our results consequently allow us to
suggest that the combination of UCMS with a high fat diet can be
used as an animal model of resistance to AD drugs. However, in
order to definitely confirm that we modelled AD resistance
induced by vascular risk factors, future studies should use different
tests that are not based on food reward such as the resident/
intruder test, the tail suspension test or the forced swim test which
have already been used to assess UCMS effects [22,35,45]. It is
also very important to generalise our results both with other AD
drugs including other SSRIs but also other classes of AD and with
other cardiovascular risk factors and finally, to check whether
these results are not related to a shift in the dose-response to
fluoxetine using higher dose of AD.
Clinical data demonstrate the need for animal models in order
to study AD resistance. We suggest that a naturalistic animal
model of AD resistance related to sub-nosographic clinical entities,
associating UCMS with cardiovascular risk factors, especially a
high fat diet regimen, could prove to be extremely useful. This
original model could serve as useful tool for future research and
eventually lead to improvements in the treatment of depression
and possibly to increased survival in patients with cardiovascular
disease by aggressively treating the cardiovascular risk factors, or
by selectively treating depression with drugs that also modify these
risk factors. Future research in this field could open up new
avenues for the development of novel AD or other treatment
strategies for these patients.
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